A Chinese research team has presented a method for screening embryos for inherited genetic disease without taking a biopsy, using DNA that embryos release into the fluid they are cultured in.
The work was described by Xie Xiaoliang, an academician of the Chinese Academy of Sciences and director of Changping Laboratory, at the annual meeting of an international reproductive genetics society held in Bangkok. The technique relies on cell-free DNA in embryo culture medium, amplified linearly so that the genome can be read at sufficient sensitivity and accuracy.
The claim that caught attention is specificity: according to the presentation, the method can identify sequences inherited from a specific grandparent, which would let clinicians trace the origin of a variant rather than simply detect its presence.
Preimplantation genetic testing currently requires removing a few cells from the embryo, a procedure that is safe in experienced hands but not free of risk, and that becomes harder as embryos are frozen and refrozen. A test that reads the medium instead would remove that step entirely.
The team’s stated next step is validation in families carrying thalassaemia, a group of inherited blood disorders that is common in southern China and across Southeast Asia, and where carrier screening and prenatal diagnosis are already routine in many provinces.
Caution is warranted. Research presented at a conference has not yet passed peer review or replicated across centres, and culture-medium DNA is present in trace amounts, which makes contamination and allele dropout the central technical risks. The distance between a convincing conference result and a clinical test is usually measured in years.
It is also the kind of technology that raises questions beyond accuracy, since easier screening expands the number of decisions that parents are asked to make. Those questions tend to arrive after the assay works, not before.

Dgcity